Cabometyx 40 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DB26FYM38
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $32,966
Award facts
- Contract value 100% obligated
- $32,966.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $32,966.42 to DMS Pharmaceutical Group Inc. for the supply of Cabometyx 40 mg tablets (30-count units) on October 20, 2025, with an ultimate completion date of October 21, 2025. This delivery order was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain and specializes in distributing branded and generic prescription medications, biologics, vaccines, and medical consumables to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent contract, valued at $499.999 billion with a completion date of December 31, 2036, was awarded on November 13, 2025, and represents the company's role as a regional prime vendor contractor supporting the broader $30.3 billion PPV-G GEN V acquisition strategy. The PPV-G GEN V program authorizes the DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide, with the contract structured to enable DMS Pharmaceutical Group to serve as a critical pharmaceutical supplier for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FYM38?
SPE2DB26FYM38 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 20, 2025.
How much is contract SPE2DB26FYM38 worth?
The government has obligated $32,966 on SPE2DB26FYM38.
Is contract SPE2DB26FYM38 an order under another contract?
Yes. SPE2DB26FYM38 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB26FYM38 competed?
The extent of competition for SPE2DB26FYM38 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award